Laboratory Products
First-In-Human Study of Novel Pneumococcal Vaccine Shows it to be Safe and Immunogenic
Jul 06 2016
ImmunoBiology Ltd, a biopharmaceutical company developing next generation anti-infective vaccines based on its proprietary ImmBioVax™ technology, reports positive results from the First-in-Human study of its novel vaccine, PnuBioVax™, against the bacterial pathogen Streptococcus pneumoniae (NCT02572635). PnuBioVax was found to be safe and well tolerated, and capable of producing antibody responses against key S. pneumoniae antigens broadly conserved across strains. The data was presented today at the International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), Glasgow, UK.
“The results of this study have demonstrated the safety of PnuBioVax in adults, and we are now looking at developing the vaccine further, focusing on the at-risk populations for pneumococcal disease of the young and the elderly,” said Dr Chris Bailey, Development Director at ImmBio.
Graham Clarke, CEO of ImmBio, commented: “Demonstrating that PnuBioVax is safe and immunogenic through this phase I clinical study is a fundamental step in our mission to create a universal vaccine against pneumococcal disease. This provides the real prospect of a strain-independent pneumococcal disease prophylactic vaccine. We are now looking for partners to progress PnuBioVax through late stage clinical development, manufacturing and marketing”.
Digital Edition
International Labmate 49.6 - Sept 2024
September 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - From R&D to QC, making NMR accessible for everyone: Putting NMR...
View all digital editions
Events
Oct 08 2024 Gothenburg, Sweden
Oct 09 2024 Birmingham, UK
Oct 09 2024 NEC, Birmingham, UK
Oct 15 2024 Milan, Italy
Oct 17 2024 Dhaka, Bangladesh